Palisade Bio Announces Presentation Of New Translational Data For PALI-2108 At 21st Congress Of ECCO In Stockholm
Benzinga Newsdesk 8 months ago
News
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven daysEncouraging safety profile across 89
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days
Encouraging safety profile across 89 subjects supports differentiated, colon-targeted PDE4 approach
Translational analyses confirm local suppression of TNF-α, JAK–STAT, NF-κB, MAPK and TGF-β signaling in colon tissue with minimal peripheral immune modulation
Data presented at the 21st Congress of the European Crohn's and Colitis Organization (ECCO) in Stockholm, Sweden
Carlsbad, CA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced the presentation of new translational data for PALI-2108 at the 21st Congress of the European Crohn's and Colitis Organization (ECCO) in Stockholm, Sweden.